XML 48 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Schedule of Condensed Statement of Operations (Details) - USD ($)
$ in Thousands
 2 Months Ended 3 Months Ended 9 Months Ended
Feb. 23, 2021
 [1]
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Business Combination and Asset Acquisition [Abstract]          
Research and development expense $ 125 $ 3,142 $ 2,615 $ 9,040 $ 8,000
General and administrative expense 5,495 4,995 18,193 13,378
Loss from operations (125) (13,604) (6,244) (38,532) (23,444)
Net loss $ (125) $ (13,800) $ (6,783) $ (28,212) $ (23,623)
[1] The condensed standalone statement of operations of Razor is provided for informational purposes only. Razor’s results for the period from January 1, 2021 through February 23, 2021 are not included in Oncocyte’s consolidated results of operations because Razor was not consolidated with Oncocyte’s financial statements but had been accounted for under the equity method of accounting since the September 30, 2019 Initial Closing date, however, Oncocyte’s results included its pro rata losses from Razor. Beginning on February 24, 2021, Razor’s results are included with Oncocyte’s consolidated results, primarily consisting of outside research and development expenses incurred by Razor for the Clinical Trial discussed above.